reviewTop 1% cited
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Gynecologic Oncology · 2013 · Vol. 130(3) · pp. 493–498
Suk‐Joon Chang✉(Ajou University)Melissa Hodeib(University of California, Irvine)Jenny Chang(University of California, Irvine)Robert E. Bristow(University of California, Irvine)
Ovarian cancer diagnosis and treatmentIntraperitoneal and Appendiceal MalignanciesEndometrial and Cervical Cancer TreatmentsMedicineInternal medicineOvarian cancerCohortStage (stratigraphy)OncologySurgeryTaxaneSurvival analysisCohort study
MeSH terms
Antineoplastic Combined Chemotherapy ProtocolsBridged-Ring CompoundsCarcinomaFemaleHumansNeoplasm StagingOvarian NeoplasmsSurvival AnalysisChemotherapy, AdjuvantPlatinum CompoundsNeoplasm, ResidualTaxoids
Citations
421
FWCI
34.34
field-weighted impact
References
44
Percentile
100%
vs. same field & year
Citations per year
Cited by
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Gynecologic Oncology · 2016 · 363 citations
References
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Cancer · 2009 · 1,581 citations
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study
Gynecologic Oncology · 2003 · 413 citations
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
American Journal of Obstetrics and Gynecology · 1994 · 670 citations
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Gynecologic Oncology · 2006 · 628 citations
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
Journal of Clinical Oncology · 2002 · 2,313 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Journal of Clinical Oncology · 2003 · 2,051 citations
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
JNCI Journal of the National Cancer Institute · 2003 · 1,126 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.